Project
INCMOR0208-301: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF TAFASITAMAB PLUS LENALIDOMIDE IN ADDITION TO RITUXIMAB VERSUS LENALIDOMIDE IN ADDITION TO RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) GRADE 1-3A OR R/R MARGINA
Ongoing - recruitment closed · 2022 until 2025
Fehr Martin, Bürki Ramona
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Ongoing - recruitment closed
Start Date
2022
End Date
2025
Financing
Industry
Study Design
Phase III
Keywords
Tafasitamab, Rituximab, Lenalidomid, Follikuläres Lym-phom, Marginalzonenlymphom, Rezidiv, Phase 3 - Studie
Partner
Syneos Health, Incyte
Labels
lymphoma
Brief description/objective
Doppel-blind, Placebo-kontrollierte, randomisierte Phase
3 Studie zur Evaluation eines zusätzlichen klinischen Benefits durch die Zugabe des CD19-Antikörpers Tafasitamab zu Rituximab-Lenalidomid bei Patienten mit rezidiviertem/refraktärem Follikulären Lymphom Grad 1-3a
oder Marginalzonenlymphom